Gynecologic Cancer

**Various Gynecologic Malignancies**

* 10409: A Phase I Dose-Escalation Clinical Trial of the Oral Combination of Triapine and Fixed Dose Olaparib-Cediranib in Patients with Primary Peritoneal Carcinoma, Ovarian Epithelial Cancer, Fallopian Tube Carcinoma, Cervical Cancer, and Uterine Cancer

**Cervical/vaginal**

10132: A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers

**Endometrial**

9892: Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer

10104: A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer (Exploratory cohort eligibility: Endometrial carcinosarcoma only)

**Ovarian**

9948: Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

**Uterine**

10150: A Randomized Phase 2 Study of Bevacizumab and Either Weekly Atezolizumab Rantavase or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: July 13, 2020